Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection

26 Jul 2020

Abstract excerpt

COVID-19 is a pandemic health emergency faced by the entire world. The clinical treatment of the severe acute respiratory syndrome (SARS) CoV-2 is currently based on the experimental administration of HIV antiviral drugs, such as lopinavir, ritonavir, and remdesivir (a nucleotide analogue used for Ebola infection). This work proposes a repurposing process using a database containing approximately 8000 known drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to COVID-19 Clinical Research Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32722574
DOI: 10.3390/v12080805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus InfectionPMID 32722574Read ↗

A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)Semantic proximity Read ↗

Interaction of Drug Candidates with Various SARS-CoV‑2 Receptors: An in Silico Study to Combat COVID-19Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and potentiality of the pre-existing drugsSemantic proximity Read ↗

Integrated Docking and Enhanced Sampling Based Selection of Repurposing Drugs for SARS-CoV-2 by Targeting Host Dependent FactorsSemantic proximity Read ↗

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.Semantic proximity Read ↗

A computational comparative analysis of the binding mechanism of molnupiravir's active metabolite to RNA‐dependent RNA polymerase of wild‐type and Delta subvariant AY.4 of SARS‐CoV‐2Semantic proximity Read ↗

Drug Repurposing of Allophenylnorstatine Containing HIV-Protease Inhibitors Against SARS-CoV-2 Mpro: Insights from Molecular Dynamics Simulations and Binding Free Energy EstimationsSemantic proximity Read ↗

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics SimulationsSemantic proximity Read ↗

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read ↗

Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19Semantic proximity Read ↗

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.